Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Proactive management eases side effects of sunitinib treatment in RCC

Staehler M et al. Ann Oncol. 2018 Aug 23. doi: 10.1093/annonc/mdy329

Key clinical point: Adverse events on adjuvant sunitinib were predictable, manageable, and reversible, while decreases in health-related quality of life were not clinically meaningful except for those related to diarrhea and loss of appetite.

Major finding: The EORTC QLQ-C30 global health status/quality of life score favored placebo, with a mean difference in the overall means of –4.76 (P greater than or equal to .0001) that did not exceed the threshold that would indicate clinically meaningful deterioration.

Study details: Analysis of adverse events and patient-reported outcomes for 306 patients treated with sunitinib in the S-TRAC (Sunitinib as Adjuvant Treatment for High-Risk Renal Cell Carcinoma Following Nephrectomy) trial.

Disclosures: Pfizer sponsored the study. The authors reported disclosures related to Pfizer, Bayer, GSK, Roche, BMS, Novartis, Exelixis, AVEO, Merck, Sanofi, Astellas, Celldex, Acerta, Janssen, and others.

Read the article.


Staehler M et al. Ann Oncol. 2018 Aug 23. doi : 10.1093/annonc/mdy329.

This Week's Must Reads

Case studies shed light on treatment for rare form of MCL , Mori S et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):e93-7.

Histopathological clues for differentiating follicular lymphomas, Servitje O et al. J Cutan Pathol. 2019;46:182-9.

Single agent daratumumab is not an option in B-cell lymphomas, Salles G et al. Clin Lymphoma Myeloma Leuk. 2019 Jan 2. doi: 10.1016/j.clml.2018.12.013.

Ibrutinib combo advances in CNS lymphoma, Grommes C et al. Blood. 2019;133(5):436-45.

Best frontline options for advanced follicular lymphoma, Shah NN et al. Clin Lymphoma Myeloma Leuk. 2019 Feb;19(2):95-102.

Must Reads in Renal Cell Carcinoma

Lower concentration of pazopanib linked with less toxicity, Noda S et al. Clin Genitourin Cancer. 2018 Dec 7. doi: 10.1016/j.clgc.2018.12.001

One-fourth of placebo arm experience adverse events in RCC trials, Chacón M et al. JAMA Network Open. 2018 Dec 7. doi: 10.1001/jamanetworkopen.2018.5617

Strong link found between RCC and melanoma, Kim KB et al. Cancer Epidemiol. 2018 Oct 19;57:80-4

Apo B/A1 predicts survival in metastatic renal cell carcinoma, Zhang F et al. Urol Oncol. 2018 Nov 30. doi: 10.1016/j.urolonc.2018.11.010

RCC patients with brain-only metastases may benefit from cytoreductive nephrectomy, Daugherty M et al. Urol Oncol. 2018 Dec 5.doi: 10.1016/j.urolonc.2018.10.021